External broker reports(aggregated public sources), Emkay Global Financial Services Limited

Emkay

External broker reports(aggregated public sources)

Emkay Global Financial Services Limited

Emkay Global Financial Services Ltd. is a leader in the financial services sector, actively creating wealth for our clients for over two decades. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<div><div><div><div><ul><li>What we liked? 1) Strong Q4 revenue growth driven by volumes amid challenging market conditions; 2) Growing focus on high-value specialty products driving mix improvement; 3) Healthy new product launch pipeline with target to launch 7 new products in FY23E; 4) Investment in new high-growth areas to sustain growth momentum in the future.</li></ul><div><div><div><div><ul><li>What we didn’t like? 1) Slow pace of cost pass through; 2) Lagging innovation momentum</li></ul><div><div><div><div><ul><li>Valuation and Outlook: We believe that Dhanuka’s healthy new product pipeline will keep up growth momentum in the domestic market, while Dahej greenfield capex will help the company to tap the export opportunity.</li></ul></div></div></div></div></div></div></div></div></div></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

What we liked? 1) Strong Q4 revenue growth driven by volumes amid challenging market conditions; 2) Growing focus on high-value specialty products driving mix improvement; 3) Healthy new product launch pipeline with target to launch 7 new products in FY23E; 4) Investment in new high-growth areas to sustain growth momentum in the future.What we didn’t like? 1) Slow pace of cost pass through; 2) Lagging innovation momentumValuation and Outlook: We believe that Dhanuka’s healthy new product pipeline will keep up growth momentum in the domestic market, while Dahej greenfield capex will help the company to tap the export opportunity.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Dhanuka Agritech - Tracking Expectations; Outlook Upbeat

External broker reports(aggregated public sources), Axis Direct

Axis Direct

<p>We downgrade rating from BUY to HOLD in light of 1) Higher channel inventory and raw material inflation, 2) Inability to pass on RM prices to consumers, and 3) Below-normal monsoon. We value DAGRI at 17x FY24E EPS to arrive at TP of Rs 940/share (previous Rs 1010/share).</p><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

We downgrade rating from BUY to HOLD in light of 1) Higher channel inventory and raw material inflation, 2) Inability to pass on RM prices to consumers, and 3) Below-normal monsoon. We value DAGRI at 17x FY24E EPS to arrive at TP of Rs 940/share (previous Rs 1010/share).Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Dhanuka Agritech: Stable Performance Amid Crisis

<p>We recommend BUY with TP of Rs. 1,010/share.</p>
<div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

We recommend BUY with TP of Rs. 1,010/share.
Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

DHANUKA: We recommend BUY with TP of Rs 1,010/share.

India

Dhanuka Agritech Ltd. manufactures insecticides, pesticides and other chemicals. The Company has a technical tie-up with M/s E.I. Dupont De Numours & Co., U.S.A. to formulate the product Methomyl 12.5L under brand name "Dunet".

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Dhanuka Agritech (DAGRI IN)

Dhanuka Agritech - Tracking Expectations; Outlook Upbeat

DAGRI delivered a healthy performance in Q4FY22, beating consensus EBITDA/PAT estimates by 11%/20%. Revenues grew by 16% YoY, beating street...

Emkay

Dhanuka Agritech: Stable Performance Amid Crisis

We downgrade rating from BUY to HOLD in light of 1) Higher channel inventory and raw material inflation, 2) Inability to pass on RM prices to...

Axis Direct

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)